Hematological dynamics following the co-administration of Resveratrol and Cisplatin in Sprague–Dawley rats.

Гематологические параметры у крыс Спрег-Доули после введения ресвератрола и цисплатина
Izuchukwu Azuka Okafor 1, Johnson Okwudili Nweke 2, Uchenna Somtochukwu Nnamah 3
More Detail
1 Department of Anatomy, Faculty of Basic Medical Sciences, College of Health Sciences, Nnamdi Azikiwe University, Nnewi, Anambra State, Nigeria
2 Department of Medical Laboratory Science, Iykenson Medical and Diagnostic Co. Ltd., Awka, Anambra State, Nigeria
3 Department of Medical Laboratory Science, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria
J CLIN MED KAZ, Volume 2, Issue 48, pp. 22-27. https://doi.org/10.23950/1812-2892-JCMK-00563
OPEN ACCESS
Download Full Text (PDF)

ABSTRACT

Background: Cisplatin, a platinum-based chemotherapy  agent, is used  in  the  effective treatment  of  a  wide  range  of  malignant cancers. Resveratrol, a polyphenolic plant-derived compound, has been shown to have several biological effects including protecting the body against several forms of damages.
Objective: This study assessed the effects of cisplatin and supplementation with resveratrol on some hematological parameters in Sprague-Dawley rats.
Material and Methods: Forty-five adult female Sprague–Dawley rats, grouped into 9, were used for this experimental study. Group 1 served as the control group and received distilled water only. Groups 2 and 9 received Cisplatin only while groups 3, 4, and 5 received different doses of Resveratrol after a single dose of Cisplatin. Groups 6, 7, and 8 received Resveratrol before Cisplatin.
Results: At the end of administration, blood samples were collected and different hematological parameters were accessed. Groups 2 and 5 showed a significantly higher Total WBC when compared to the control group (p<0.05). Group 7 showed a significantly higher (p<0.05) neutrophil count compared to both the control group and group 2, but a significant decrease in the lymphocyte count compared to the same groups (p<0.05). Groups 6 and 7 showed a significant reduction in monocyte when compared to the control group (p<0.05). There was no significant difference in the eosinophil count of all treatment groups when compared to the control group and cisplatin groups (p<0.05). Basophil increased significantly in group 7 when compared to the control group and group 2 (p<0.05). More so, a significant decrease in the Haemoglobin (Hb), Packed cell volume (PCV) and Mean corpuscular volume (MCV) level were observed when compared to group 9 (p<0.05).
Conclusion: This study showed that cisplatin-induced alteration in some hematological parameters is reversible by treatment with resveratrol. More so, resveratrol supplementation should be incorporated as part of dietary nutrients for patients on cisplatin during chemotherapy.

CITATION

Okafor IA, Nweke JO, Nnamah US. Hematological dynamics following the co-administration of Resveratrol and Cisplatin in Sprague–Dawley rats.. Journal of Clinical Medicine of Kazakhstan. 2018;2(48):22-7. https://doi.org/10.23950/1812-2892-JCMK-00563

REFERENCES

  • Marković SD, Djačić DS, Cvetković DM, Obradović, A.D., Žižić, J.B., Ognjanović, BI, et al. Effects of acute in vivo cisplatin and selenium treatment on hematological and oxidative stress parameters in red blood cells of rats. Biol. Trace. Elem. Res. 2010; DOI 10.1007/s12011010-8788-9.
  • Taguchi NA, Abid MR et al. Cisplatin-associated nephrotoxicity and pathological events. Contrib Nephrol. 2005; 148:107–121.
  • Wood PA, Hrusheeky WJM. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest. 1995; 95:1650– 1659.
  • Von Hoff DD, Schilsky R, Richert CM. Toxic effects of cis-dichlorodiammine platinum (II) in man. Cancer Treat. Rep. 1979; 63, 1527-1531.
  • Philipps KA, Tannock IF. Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. J. Clin. Oncol. 1998; 16, 3179-3190. 
  • Hişmioǧulları SE, Hişmioǧulları AA, Yavuz MT. The protective effect of resveratrol in experimentally induced non-sterile clean wound inflammation in rats. Kafkas universitesi Veteriner Fakultesi Dergisi 2013; 19, supplement A, pp. A1-A5.
  • Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH. Vinblastine plus ifosphamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J. Clin. Oncol. 1998; 16:2500–2504.
  • Bolis G, Favalli G, Danese S, Zanaboni F, Mangili G, Scarabelli C, et al. Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer. J. Clin. Oncol. 1997;15:1938– 1944.
  • Rose P, Bundy B, Watkins E, Thigpen J, Deppe G, Maiman M, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N. Engl. J. Med. 1999;340:1144–1153.
  • Coppin C, Gospodarowicz M, James K, Tannock I, Zee B, Carson J, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J. Clin. Oncol. 1996;14:2901–2907.
  • Planting A, Catimel G, de Mulder P, de Graeff A, Hoppener F, Verweij J, et al. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. Ann. Oncol.1999;10:693–700.
  • Levi JA, Aroney RS, Dalley DN. Haemolytic anaemia after cisplatin treatment. BMJ. 1981; 282: 2003- 2004.
  • Maloisel F, Kurtz JE, Andres E, Gorodetsky C, Dufour P, Oberling F. Platin salts-induced haemolytic anaemia: cisplatin and the first case of carboplatin-induced haemolysis. Anticancer drugs. 1995; 6(2): 324 – 326.
  • Donnelly LE, Newton R, Kennedy GE. Anti inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. The American Journal of Physiology: Lung cellular and molecular physiology. 2004; 287(4): L774-L783.
  • Olas B, Wachowicz B, Majsterek I, Blasiak J. Resveratrol may reduce oxidative stress induced by platinum compounds in human plasma, blood platelets and lymphocytes. Anticancer Drugs. 2005; 16: 659-665.
  • Mukai K, Galli SJ. Basophils. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net 2013 [doi: 10.1002/9780470015902. a0001120.pub3]
  • Calvert AH, Nevell DR. Cisplatin triggers platelet activation. Journal of Clinical Oncology, 1989; 7(11):1748.